HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J Am Dent Assoc, Vol 131, No 12, 1729-1737. © 2000 American Dental Association

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MORRISON, B. W. Articles by MEHLISCH, D. Search for Related Content PubMed PubMed Citation Articles by MORRISON, B. W. Articles by MEHLISCH, D. Related Collections Pharmacology

Background. Rofecoxib, which specifically inhibits cyclooxygenase-2, is indicated for relief of the signs and symptoms of osteoarthritis and for the management of acute pain in adults. The authors present an overview of six placebo-controlled trials designed to evaluate the single-dose analgesic efficacy of a range of doses of rofecoxib in the treatment of postoperative dental pain.

Methods. The six studies included doses of rofecoxib ranging from 7.5 to 500 milligrams. Maximal analgesic doses of a nonsteroidal anti-inflammatory drug, or NSAID, either naproxen sodium (550 mg) or ibuprofen (400 mg), were used as active comparators in each study. Analgesic efficacy was assessed with the use of validated self-administered questionnaires. The primary endpoint in each study was the total pain relief over the eight-hour postdose period. Additional endpoints were used to characterize the onset of analgesia and peak analgesic effect.

Results. The results of these studies demonstrated that the efficacy of rofecoxib was dose-related, with 50 mg being consistently more effective than placebo for all measures of analgesic efficacy. Moreover, 50 mg was the lowest dose that reproducibly demonstrated an analgesic effect comparable to the effect of maximum single analgesic doses of NSAIDs.

Conclusion. The results of these studies support the recommended dose of 50 mg of rofecoxib once daily for the management of pain.

Clinical Implications. Rofecoxib, at a dose of 50 mg, is effective in the management of postoperative dental pain.

This article has been cited by other articles:

				I. D. Jackson, B. H. Heidemann, J. Wilson, I. Power, and R. D. Brown Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry Br. J. Anaesth., May 1, 2004; 92(5): 675 - 680. [Abstract] [Full Text] [PDF]

				H. Ma, J. Tang, P. F. White, A. Zaentz, R. H. Wender, A. Sloninsky, R. Naruse, R. Kariger, R. Quon, D. Wood, et al. Perioperative Rofecoxib Improves Early Recovery After Outpatient Herniorrhaphy Anesth. Analg., April 1, 2004; 98(4): 970 - 975. [Abstract] [Full Text] [PDF]

				N. M. Gajraj Cyclooxygenase-2 Inhibitors Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738. [Full Text] [PDF]

				M. F. Watcha, T. Issioui, K. W. Klein, and P. F. White Costs and Effectiveness of Rofecoxib, Celecoxib, and Acetaminophen for Preventing Pain After Ambulatory Otolaryngologic Surgery Anesth. Analg., April 1, 2003; 96(4): 987 - 994. [Abstract] [Full Text] [PDF]

				E. Niederberger, I. Tegeder, C. Schafer, M. Seegel, S. Grosch, and G. Geisslinger Opposite Effects of Rofecoxib on Nuclear Factor-kappa B and Activating Protein-1 Activation J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1153 - 1160. [Abstract] [Full Text] [PDF]